Published on
February 11, 2026
- 23:55 GMT
Isosceles Pharmaceuticals Announces Acceptance of IPI201 for Phase I First-in-Human Clinical Trial
Novel intravenous anti-inflammatory candidate advances to Phase I evaluation to assess safety, tolerability, and pharmacokinetics. WILMINGTON, NC, UNITED STATES, February 11, 2026 /EINPresswire.com/ -- Isosceles Pharmaceuticals today announced that its …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
